Literature DB >> 18791656

Combined glucosamine and chondroitin sulfate provides functional and structural benefit in the anterior cruciate ligament transection model.

Francisco Saraiva Silva1, Natalino Hajime Yoshinari, Rondinelle Ribeiro Castro, Virgínia Cláudia Carneiro Girão, Margarida Maria Lima Pompeu, Judith Pessoa de Andrade Feitosa, Francisco Airton Castro Rocha.   

Abstract

Evidence that combined glucosamine sulfate and chondroitin sulfate (Gluchon) or isolated glucosamine (Glu) modifies joint damage in osteoarthritis (OA) is still lacking. We studied joint pain and cartilage damage using the anterior cruciate ligament transection (ACLT) model. Wistar rats were subjected to ACLT of the right knee (OA) or sham operation. Groups received either Glu (500 mg/kg), Gluchon (500 mg/kg glucosamine +400 mg/kg chondroitin) or vehicle (non-treated--NT) per os starting 7 days prior to ACLT until sacrifice at 70 days. Joint pain was evaluated daily using the rat-knee joint articular incapacitation test. Structural joint damage was assessed using histology and biochemistry as the chondroitin sulfate (CS) content of cartilage by densitometry (microgram per milligram dried cartilage), comparing to standard CS. The molar weight (Mw) of the CS samples, used as a qualitative biochemical parameter, was obtained by comparing their relative mobility on a polyacrylamide gel electrophoresis to standard CS. Gluchon, but not Glu, significantly reduced joint pain (P < 0.05) compared to NT. There was an increase in CS content in the OA group (77.7 +/- 8.3 microg/mg) compared to sham (53.5 +/- 11.2 microg/mg) (P < 0.05). The CS from OA samples had higher Mw (4:62 +/- 10(4) g/mol) compared to sham (4:18 +/- 0.19 x 10(4) g/mol) (P < 0.05). Gluchon administration significantly reversed both the increases in CS content (54.4 +/- 12.1 microg/mg) and Mw (4:18 +/- 0.2 x 10(4) g/mol) as compared to NT. Isolated Glu decreased CS content though not reaching statistical significance. Cartilage histology alterations were also significantly prevented by Gluchon administration. Gluchon provides clinical (analgesia) and structural benefits in the ACLT model. This is the first demonstration that biochemical alterations occurring in parallel to histological damage in OA are prevented by Gluchon administration.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18791656     DOI: 10.1007/s10067-008-0988-8

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  33 in total

1.  Glucosamine decreases expression of anabolic and catabolic genes in human osteoarthritic cartilage explants.

Authors:  E J Uitterlinden; H Jahr; J L M Koevoet; Y M Jenniskens; S M A Bierma-Zeinstra; J Degroot; J A N Verhaar; H Weinans; G J V M van Osch
Journal:  Osteoarthritis Cartilage       Date:  2005-11-18       Impact factor: 6.576

2.  Osteoarthritis cartilage histopathology: grading and staging.

Authors:  K P H Pritzker; S Gay; S A Jimenez; K Ostergaard; J-P Pelletier; P A Revell; D Salter; W B van den Berg
Journal:  Osteoarthritis Cartilage       Date:  2005-10-19       Impact factor: 6.576

3.  Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study.

Authors:  Karel Pavelká; Jindriska Gatterová; Marta Olejarová; Stanislav Machacek; Giampaolo Giacovelli; Lucio C Rovati
Journal:  Arch Intern Med       Date:  2002-10-14

4.  Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial.

Authors:  J Y Reginster; R Deroisy; L C Rovati; R L Lee; E Lejeune; O Bruyere; G Giacovelli; Y Henrotin; J E Dacre; C Gossett
Journal:  Lancet       Date:  2001-01-27       Impact factor: 79.321

5.  In vivo chondroprotection and metabolic synergy of glucosamine and chondroitin sulfate.

Authors:  L Lippiello; J Woodward; R Karpman; T A Hammad
Journal:  Clin Orthop Relat Res       Date:  2000-12       Impact factor: 4.176

6.  Reliability, reproducibility and variability of the traditional Histologic/Histochemical Grading System vs the new OARSI Osteoarthritis Cartilage Histopathology Assessment System.

Authors:  R J H Custers; L B Creemers; A J Verbout; M H P van Rijen; W J A Dhert; D B F Saris
Journal:  Osteoarthritis Cartilage       Date:  2007-06-18       Impact factor: 6.576

7.  A quantitative approach to measure joint pain in experimental osteoarthritis--evidence of a role for nitric oxide.

Authors:  R R Castro; F Q Cunha; F S Silva; F A C Rocha
Journal:  Osteoarthritis Cartilage       Date:  2006-03-31       Impact factor: 6.576

8.  Reactive nitrogen species scavenging, rather than nitric oxide inhibition, protects from articular cartilage damage in rat zymosan-induced arthritis.

Authors:  Mirna Marques Bezerra; Susan D Brain; Stan Greenacre; Selma Maria Bezerra Jerônimo; Liana Batista de Melo; Julie Keeble; Francisco Airton Castro da Rocha
Journal:  Br J Pharmacol       Date:  2003-12-08       Impact factor: 8.739

Review 9.  OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines.

Authors:  W Zhang; R W Moskowitz; G Nuki; S Abramson; R D Altman; N Arden; S Bierma-Zeinstra; K D Brandt; P Croft; M Doherty; M Dougados; M Hochberg; D J Hunter; K Kwoh; L S Lohmander; P Tugwell
Journal:  Osteoarthritis Cartilage       Date:  2008-02       Impact factor: 6.576

10.  Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis.

Authors:  Daniel O Clegg; Domenic J Reda; Crystal L Harris; Marguerite A Klein; James R O'Dell; Michele M Hooper; John D Bradley; Clifton O Bingham; Michael H Weisman; Christopher G Jackson; Nancy E Lane; John J Cush; Larry W Moreland; H Ralph Schumacher; Chester V Oddis; Frederick Wolfe; Jerry A Molitor; David E Yocum; Thomas J Schnitzer; Daniel E Furst; Allen D Sawitzke; Helen Shi; Kenneth D Brandt; Roland W Moskowitz; H James Williams
Journal:  N Engl J Med       Date:  2006-02-23       Impact factor: 91.245

View more
  6 in total

1.  Anti-inflammatory and immunomodulatory effect of an extract of Coccidioides posadasii in experimental arthritis.

Authors:  Ana Carolina Matias Dinelly Pinto; Rossana de Aguiar Cordeiro; José Julio Costa Sidrim; Ana Karine Rocha de Melo Leite; Ana Caroline Rocha de Melo Leite; Virgínia Cláudia Carneiro Girão; Raimunda Sâmia Nogueira Brilhante; Marcos Fábio Gadelha Rocha; Fernando de Queiroz Cunha; Francisco Airton Castro Rocha
Journal:  Mycopathologia       Date:  2013-02-05       Impact factor: 2.574

2.  Combined glucosamine and chondroitin sulfate, once or three times daily, provides clinically relevant analgesia in knee osteoarthritis.

Authors:  José Roberto Provenza; Samuel Katsuyuki Shinjo; Joyce Macedo Silva; Carla Rosana Goulart Silva Peron; Francisco Airton Castro Rocha
Journal:  Clin Rheumatol       Date:  2014-08-03       Impact factor: 2.980

3.  Chondroitin sulfate and glucosamine sulfate associated to photobiomodulation prevents degenerative morphological changes in an experimental model of osteoarthritis in rats.

Authors:  Marcella Sanches; Lívia Assis; Cyntia Criniti; Danilo Fernandes; Carla Tim; Ana Claudia Muniz Renno
Journal:  Lasers Med Sci       Date:  2017-12-01       Impact factor: 3.161

Review 4.  Is there any scientific evidence for the use of glucosamine in the management of human osteoarthritis?

Authors:  Yves Henrotin; Ali Mobasheri; Marc Marty
Journal:  Arthritis Res Ther       Date:  2012-01-30       Impact factor: 5.156

5.  The Fate of Oral Glucosamine Traced by (13)C Labeling in the Dog.

Authors:  George R Dodge; Ravinder R Regatte; Elizabeth A Noyszewski; Jeffery O Hall; Akella V Sharma; D Allen Callaway; Ravinder Reddy
Journal:  Cartilage       Date:  2011-07       Impact factor: 4.634

Review 6.  Glucosamine and Chondroitin Sulfate: Is There Any Scientific Evidence for Their Effectiveness as Disease-Modifying Drugs in Knee Osteoarthritis Preclinical Studies?-A Systematic Review from 2000 to 2021.

Authors:  Silvia Fernández-Martín; Antonio González-Cantalapiedra; Fernando Muñoz; Mario García-González; María Permuy; Mónica López-Peña
Journal:  Animals (Basel)       Date:  2021-05-29       Impact factor: 2.752

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.